Nilotinib

Nilotinib selectively blocks the BCR‑ABL tyrosine kinase as well as KIT and PDGFR receptors. By inhibiting these enzymes, it stops downstream signaling that promotes malignant cell growth and survival, leading to reduced proliferation of leukemic cells and increased programmed cell death.

The exact dose of Nilotinib is determined by the prescribing physician based on the patient’s disease phase, weight, liver function, and other clinical factors. While a common starting regimen may be 300 mg taken twice daily, the final dosing schedule must be individualized and confirmed by a qualified healthcare professional.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is contraindicated during pregnancy, and effective contraception is required for both men and women of reproductive potential. Use while breastfeeding is not recommended because the drug can be excreted in breast milk.

To request Nilotinib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Nilotinib is a second‑generation tyrosine kinase inhibitor offering higher potency against BCR‑ABL than the first‑generation drug imatinib. Compared with another second‑generation agent, dasatinib, nilotinib has a different safety profile—more QT‑prolongation risk but less pleural effusion. Choice of therapy depends on disease characteristics, prior treatment, and patient tolerance.

Store Nilotinib tablets at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct light. Do not store in the bathroom or near a kitchen sink. Keep out of reach of children and dispose of any unused tablets according to local regulations.

Nilotinib is taken orally as a tablet, usually on an empty stomach—at least one hour before or two hours after a meal—to ensure optimal absorption. The tablets should be swallowed whole with a full glass of water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most critical safety concerns include QT interval prolongation, which can lead to serious heart rhythm disturbances; severe liver injury indicated by marked elevation of liver enzymes; pancreatitis presenting with abdominal pain; and profound reductions in blood cell counts such as neutropenia or thrombocytopenia. Prompt medical attention is required if any of these symptoms arise.

Nilotinib should be avoided in patients with known hypersensitivity to the drug, those with a prolonged QT interval, severe hepatic impairment, or uncontrolled infections. It is also contraindicated during pregnancy and is not recommended for breastfeeding mothers. Physicians must evaluate each individual’s medical history before initiating therapy.